Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999084 · ClinicalTrials.gov registry record
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
A clinical trial of Alzheimer Disease, sponsored by Emory University.
- Recruiting
- Registry status
- 735
- Enrollment target
- 8
- Study locations
NCT05999084: Recruiting study of Alzheimer Disease, sponsored by Emory University.
NCT05999084 is a study of Alzheimer Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 735 participants, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (73% lower). The trial reports 8 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05999084, a study of Alzheimer Disease, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 735 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
Conditions Studied
Interventions
- DRUG Anti-amyloid Monoclonal Antibodies (mAbs)
- COMBINATION_PRODUCT Standard of Care
Study Locations (8)
Georgia
- Georgia Memory Net Memory Assessment Clinic - Albany - Albany
- Georgia Memory Net Memory Assessment Clinic - Atlanta - Atlanta
- Emory Clinic - Atlanta
- Georgia Memory Net Memory Assessment Clinic - Augusta - Augusta
- Georgia Memory Net Memory Assessment Clinic - Gainesville - Gainesville
- Georgia Memory Net Memory Assessment Clinic - Macon - Macon
- Georgia Memory Net Memory Assessment Clinic - Savannah - Savannah
- Georgia Memory Net Memory Assessment Clinic - Vidalia - Vidalia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2028-07 |
What NCT05999084 shows while recruiting
NCT05999084 is an observational study that tracks outcomes without assigning an intervention. The registered 735 participants enrollment target is mid-sized for trials with a published cap, below the 2,748-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Anti-amyloid Monoclonal Antibodies (mAbs) is the first listed.
NCT05999084 lists 8 locations in 1 state (Georgia).
Frequently Asked Questions
What is clinical trial NCT05999084 about?
NCT05999084 is a clinical study titled "Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry". The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
What is the current status of trial NCT05999084?
This trial is currently recruiting. The enrollment target is 735 participants. The study started on 2025-03-06. Estimated completion is 2028-07.
What conditions does trial NCT05999084 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT05999084?
The interventions under investigation include: Anti-amyloid Monoclonal Antibodies (mAbs) (DRUG), Standard of Care (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05999084?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05999084 being conducted?
This trial has 8 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05999084's enrollment target sits among peer trials
735 41st of 306 higher than 266 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT06825689 · 735 participants · NA
Unidos Contra el VPH
- NCT05796141 · 736 participants · NA
Becoming United in Lifestyle Decisions
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI